Cover Image
市場調查報告書

Stearoyl-CoA去飽和酶:開發平台分析

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 359832
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
Stearoyl-CoA去飽和酶:開發平台分析 Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Review, H1 2016
出版日期: 2016年05月18日 內容資訊: 英文 50 Pages
簡介

本報告提供以Stearoyl-CoA去飽和酶為標的的藥物適應症,開發階段,作用機制,給藥途徑及各分子類型分析,藥物的藥理作用之相關記述,並彙整迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

Stearoyl-CoA去飽和酶概要

治療藥的開發

Stearoyl-CoA去飽和酶:開發中的產品 - 各開發階段

Stearoyl-CoA去飽和酶:開發中的產品 - 治療範圍別

Stearoyl-CoA去飽和酶:開發中的產品 - 各適應症

Stearoyl-CoA去飽和酶:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

Stearoyl-CoA去飽和酶:企業開發中的產品

Stearoyl-CoA去飽和酶:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

Stearoyl-CoA去飽和酶治療藥的開發企業

  • 第一三共
  • Galmed Pharmaceuticals Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Novartis AG
  • Sanofi
  • Xenon Pharmaceuticals Inc.

藥物簡介

Stearoyl-CoA去飽和酶:暫停中的計劃

Stearoyl-CoA去飽和酶:開發中止的產品

Stearoyl-CoA去飽和酶:主要消息和新聞稿

附錄

目錄
Product Code: GMDHC0038TDB

Summary

Global Markets Direct's, 'Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Review, H1 2016', provides in depth analysis on Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1)
  • The report reviews Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) Overview
    • Therapeutics Development
  • Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Stage of Development
  • Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Therapy Area
  • Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Indication
  • Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Companies
  • Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Companies Involved in Therapeutics Development
    • Daiichi Sankyo Company, Limited
    • Galmed Pharmaceuticals Ltd.
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Novartis AG
    • Sanofi
    • Xenon Pharmaceuticals Inc.
  • Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Drug Profiles
    • Aramchol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-1940029 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-224 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit SCD1 for Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XEN-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Dormant Projects
  • Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Discontinued Products
  • Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Featured News & Press Releases
    • Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease
    • Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study
    • Feb 10, 2016: Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne
    • Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease
    • Sep 24, 2015: Xenon Pharmaceuticals Announces Initiation of XEN801 Phase 1 Clinical Trial
    • Aug 13, 2015: Galmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America
    • Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States
    • Jan 28, 2015: Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production
    • Dec 01, 2014: Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers
    • Nov 13, 2014: Galmed Pharmaceuticals Announces First Administration of Aramchol in its Phase IIa Trial for the Treatment of Cholesterol Gallstones
    • Sep 23, 2014: Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH
    • Sep 02, 2014: Galmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events
    • Jul 22, 2014: Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders
    • Jul 08, 2014: Galmed Announces Publication of Aramchol Phase IIa Trial in the Clinical Gastroenterology and Hepatology Journal
    • Jun 09, 2014: Galmed Pharmaceuticals Announces the Filing of a Provisional Patent Application for the Use of Aramchol for the Treatment of Lipodystrophy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Pipeline by Galmed Pharmaceuticals Ltd., H1 2016
  • Pipeline by GlaxoSmithKline Plc, H1 2016
  • Pipeline by Johnson & Johnson, H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by Sanofi, H1 2016
  • Pipeline by Xenon Pharmaceuticals Inc., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top